Loading
Exagen Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 19 Nov 2024.
Exagen Inc.: what insiders have been doing
Headquartered in Vista, United States, Exagen Inc. belongs to the Healthcare & Pharma sector and traces its origins to 2002. Filings by its managers are published through SEC (Form 4). Between 18 October 2025 and 18 October 2026, 2 insiders published 6 filings.
The flow runs one way only: 4 sales worth €409k, from 2 insiders, and no purchase. At €321k, the sale published on 20 October 2025 by Aballi John is the largest of the period (0.37% of market cap).
Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
With 6 filings in twelve months, the company is quieter than the median of 19 filings across the 5,812 companies we follow on the same exchange. Since 2021, the database holds 6 purchases and 17 sales by insiders of the company.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Cytosorbents Corp. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Key facts
Headquarters: Vista, United States · Founded: 2002
Source: Wikidata (CC0).
Insider Decl.
45
Thresholds
n/a
Buy Volume
€440,833
6 ops. · all time
Sell Volume
€3M
17 ops. · all time
Who traded when
BuySaleJohn Aballi1 buy3 sales
Jeffrey G. Black1 buy2 sales
NMSIC Co-Investment Fund, L.P.2 sales
Since the insiders bought
- +85.0%Entry US$4.20 · Close at T+365 US$7.77
- +124.1%Entry US$3.53 · Close at T+365 US$7.91
- -37.6%Entry US$3.14 · Close at T+365 US$1.96
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 21,477 of 24,158 companies
23.4
score / 100
Value18
Quality29
FCF yld-7.0%
Earn yld-9.8%
EV/EBITDA·
ROE-114%
Gross mgn58%
Net mgn-30%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$8.42
Analyst consensus
7 analysts1.00/5
US$9.00Target US$10.14(+20%)US$12.00
Income statement
RevenueUS$66.6M
Gross profitUS$38.8M58% margin
EBITDA-US$13.5M-20% margin
Net income-US$20M-26.6% margin
Valuation
PER (forward)-17.9x
P/Book16.7x
Beta2.12
Balance sheet & cash
Market capUS$204M
Total debtUS$25.7M
Free Cash Flow-US$14.3M
Debt / Equity226%
Profitability & ownership
ROE-113.8%
ROA-14.9%
% insiders24.3%
% institutions44.9%
Last declaration on 16 March 2026
Declarations45 total
150,000 shares0Common StockSEC:0001843113-26-000006:0
75,000 shares@ US$3.1646.1% of flowCommon StockSEC:0001449439-26-000005:0
15,698 shares@ US$3.625.5% of flowCommon StockSEC:0001843113-26-000004:0
1,584 shares@ US$3.610.0055% mcap1.1% of flowCommon StockSEC:0001449439-26-000003:0
11,430 shares@ US$3.610.040% mcap4.0% of flowCommon StockSEC:0001843113-26-000002:0
31,787 shares@ US$11.81610.37% mcap36.4% of flowCommon StockSEC:0001843113-25-000003:0
20,466 shares@ US$9.790.20% mcap38.7% of flowCommon StockSEC:0001628280-25-041688:0
350,000 shares@ US$3.3063.2% of flowCommon StockSEC:0001140361-25-010700:0
8,621 shares@ US$2.4652.3% of flowCommon StockSEC:0001274737-25-000013:0
112,500 shares0Common StockSEC:0001274737-25-000010:0
15,000 shares0Common StockSEC:0001274737-25-000011:0
200,000 shares@ US$3.300236.8% of flowCommon StockSEC:0001140361-24-047978:0
22,298 shares@ US$2.9814.2% of flowCommon StockSEC:0001274737-24-000096:0
Canonical exit: 13 Feb 2025 (T+90)
24,305 shares@ US$2.817.3% of flowCommon StockSEC:0001274737-24-000094:0
Canonical exit: 12 Feb 2025 (T+90)
225,000 shares0Common StockSEC:0001274737-24-000084:0
40,401 shares@ US$1.928.1% of flowCommon StockSEC:0001274737-24-000052:0
Canonical exit: 14 Aug 2024 (T+90)
9,297 shares@ US$1.908922.8% of flowCommon StockSEC:0001274737-24-000017:0
9,804 shares@ US$1.912.0% of flowCommon StockSEC:0001274737-24-000015:0
175,000 shares0Common StockSEC:0001274737-24-000012:0
75,000 shares0Common StockSEC:0001274737-24-000013:0
6,738 shares@ US$1.949117.1% of flowCommon StockSEC:0001274737-24-000009:0
33,819 shares@ US$1.74516.3% of flowCommon StockSEC:0001274737-23-000094:0
9,803 shares@ US$2.1422.2% of flowCommon StockSEC:0001274737-23-000091:0
167 shares@ US$3.11050.2% of flowCommon StockSEC:0000899243-23-015986:0
Canonical exit: 13 Sept 2023 (T+90)
3,667 shares0Common StockSEC:0001274737-23-000013:0
25 of 45 declarations
About Exagen Inc.
Exagen Inc. is a U.S. medical technology company focused on autoimmune and rheumatology diagnostics. The company is listed on the Nasdaq market in the United States under the ticker XGN. Its business centers on developing and commercializing the AVISE® portfolio of laboratory tests, which are designed to support differential diagnosis, prognosis, and monitoring of complex rheumatic, autoimmune, and autoimmune-related diseases, including systemic lupus erythematosus and rheumatoid arthritis. The flagship AVISE® CTD test was commercially launched in 2012 and remains the core revenue driver. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1274737/000127473725000019/exdx-20241231.htm))
Exagen was founded in 2002, originally incorporated in New Mexico, before moving to Delaware in 2003. The company adopted its current name, Exagen Inc., in January 2019. Its principal executive offices are in Vista, California, giving it a U.S. headquarters in an active life-sciences region. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1274737/000127473726000009/exdx-20251231.htm))
Read moreShow less
From a business-model perspective, Exagen is a focused specialist rather than a broad-based diagnostics conglomerate. Its competitive positioning rests on proprietary biomarkers, peer-reviewed clinical evidence, and a diagnostic workflow aimed at solving a major pain point in autoimmune care: overlapping symptoms that can delay diagnosis and lead to repeated testing. Management describes the company as serving rheumatologists, primary care physicians, other specialists, patients, hospitals, healthcare systems, and payors, with operations reported as a single segment. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1274737/000127473725000019/exdx-20241231.htm))
The main product line remains the AVISE® platform, with AVISE® CTD at the center. In recent periods, Exagen has expanded the platform with new biomarkers, including markers targeting seronegative rheumatoid arthritis and T-cell-related biology, aiming to improve clinical differentiation and widen the company’s addressable use cases. The company has also emphasized higher average selling prices, which suggests improved product mix and better commercial traction. ([investors.exagen.com](https://investors.exagen.com/node/9596/pdf))
Recent operating updates point to an improving turnaround story. For full-year 2025, Exagen reported record revenue of $66.6 million, up 20% year over year, alongside higher AVISE CTD test volumes and improved gross margin. In the first quarter of 2026, the company again reported record quarterly revenue of $17.3 million and ended the period with roughly $22 million in cash and cash equivalents. Management also guided to 2026 revenue of $70 million to $73 million and highlighted continued commercial expansion of the AVISE platform. ([investors.exagen.com](https://investors.exagen.com/node/9596/pdf))
For investors in French-speaking markets, Exagen is best viewed as a Nasdaq-listed U.S. healthcare diagnostics company with a differentiated niche in autoimmune disease testing. The investment case combines a specialized clinical moat and improving revenue momentum, but remains exposed to reimbursement risk, regulatory scrutiny, and the need to sustain commercial execution and funding discipline. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1274737/000127473726000009/exdx-20251231.htm))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
